BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal
BioXcel Therapeutics, Inc. (BTAI)
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Clinical benefit observed in 10 of 10 patients; Human proof-of-concept established Clinical opioid withdrawal symptoms during an escalating infusion of Dex (10 subjects) vs. placebo (5 subjects). Once symptoms reduced by = 50% the infusion was stopped and symptoms measured 30 minutes later. For subjects who did not achieve a reduction, after 3 hours the infusion was stopped and symptoms measured 30 minutes later. Provides further evidence of BXCL501’s mechanism of action Expands clinical advisory board with four additional industry leaders to guide on global development and market expansion of BXCL501 NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced proof-of-concept data from its Phase 1b study of intraven
Show less
Read more
Impact Snapshot
Event Time:
BTAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BTAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BTAI alerts
High impacting BioXcel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BTAI
News
- BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia [Yahoo! Finance]Yahoo! Finance
- BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaGlobeNewswire
- BioXcel launches $25M direct offering of stock and warrants [Seeking Alpha]Seeking Alpha
- Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack [Seeking Alpha]Seeking Alpha
- BioXcel Therapeutics Announces $25 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
BTAI
Earnings
- 3/12/24 - Beat
BTAI
Sec Filings
- 4/10/24 - Form 8-K
- 4/8/24 - Form 4
- 4/8/24 - Form 4
- BTAI's page on the SEC website